Genzyme gets EU nod for Aubagio; NICE OKs Novartis' Jetrea; Study finds therapeutic drug subbing saves money;

@FiercePharma: Bayer's new cancer drug Stivarga (with Onyx) wins approval in Europe, for metastatic colorectal. Release | Follow @FiercePharma

@EricPFierce: J&J takes another step to warn consumers that if you take too much acetaminophen, it will kill you. Story | Follow @EricPFierce

@CarlyHFierce: Cubist recalls four lots of antibiotic Cubicin because of glass particles. More from FiercePharmaManufacturing | Follow @CarlyHFierce

> Sanofi's ($SNY) Genzyme said the European Commission has approved Aubagio, its once-daily pill for treating adults with relapsing remitting multiple sclerosis. Release

> The National Institute for Health and Care Excellence (NICE) has recommended Novartis' ($NVS) Jetrea in the U.K. for treatment of a rare eye condition called vitreomacular traction. Story

> A study found that therapeutic drug substitutions, using less expensive substitutes that are not equivalent but have a similar treatment effect as the original medication, could save payers about three times more than generics. Story

> An FDA official in India says the agency is not specifically targeting Indian companies for enforcement. Story

Medical Device News

@FierceMedDev: Meda grabs MA maker of asthma inhaler for $135M. Story | Follow @FierceMedDev

@MarkHFierce: Covidien won yet another patent battle with a rival. Patent spats aren't cheap. News | Follow @MarkHFierce

@MichaelGFierce: European public health group gets behind tighter device controls. Item | Follow @MichaelGFierce

> Texas neurostim startup pulls in $3.4M for multiple trials. Article

> Medtronic looks to innovate with new Singapore shop. More

> Covidien claims victory in surgical tool patent dustup. Story

Biotech News

@FierceBiotech: Report: Big CROs soared 10% last year. More from FierceCRO | Follow @FierceBiotech

@RyanMFierce: Icon Bioscience snags $15M in B round for eye therapies. News | Follow @RyanMFierce

@EmilyMFierce: ICYMI: UM Pharmacy School researchers develop new opioid pain drug that decreases tolerance, side effects. Article | Follow @EmilyMFierce

> Report: Clarus, OrbiMed pioneer paths to biotech VC victories. Story

> Meda to scoop up Sequoia-backed pharma startup Acton for $135M. Report

> Johnson & Johnson inks R&D pact to fight growing threat of dengue infections. More

And Finally... A design award has gone to Kanupriya Goel and biologist Gautam Goel for a drug label that reacts over time to reveal a hidden message that the drug is expired. Story


Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.